Autopsy report · NCT04904276

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

“met minimum enrollment goal, however, enrollment was slow due to the pandemic, therefore, the study was terminated”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 6 months before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Rigel Pharmaceuticals

Sponsor type

Industry

Conditions

ITP; Immune Thrombocytopenia

Interventions

Fostamatinib

Participants

16

Sites

14

Countries

United States

Trials that died the same way

• Changing Developmental Trajectories Through Early Treatment
  “Participant enrollment was hindered by the COVID-19 pandemic and the study was ultimately terminated.” (82% match in meaning)
• The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
  “This study was prematurely terminated due to low enrollment” (80% match in meaning)
• MIRACLE EF Clinical Study
  “The study was terminated early due to low enrollment.” (80% match in meaning)
• Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
  “The study was prematurely terminated by the Sponsor based on difficulties in meeting enrollment goals, especially during the COVID-19 pandemic, and not for reasons relating to any concerns regarding quality, safety, or efficacy.” (80% match in meaning)
• A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
  “Due to low enrollment, this study was terminated early.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.